Next 10 |
NEW YORK , June 5, 2019 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the lists of downgrades from its respective OTCQX® and OTCQB® markets and Caveat Emptor Desig...
VALENCIA, SPAIN, March 20, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Zenosense, Inc. (OTCQB: ZENO, "Zenosense", the "Company"), a healthcare technology company focused on the development and commercialization of the MIDS Cardiac™ hand-held technology for the early detection o...
Agreement signed with third party investor to fund up to $1.2 million to support next crucial development phase of MIDS Cardiac POC diagnostic device Patented MIDS technology has successfully detected commercial assay beads at a level approximately four times better than the threshold adv...
Healthcare technology company Zenosense (OTC: ZENO) this morning announced that, in support of the next phase of development of MIDS Cardiac, its MIDS Medical Ltd. (“MML”) joint venture (“JV") has expanded its technical team. MML has engaged three key contractors following...
VALENCIA, SPAIN, Oct. 02, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Zenosense, Inc. (OTCQB: ZENO, "Zenosense", the "Company"), a healthcare technology company focused on the development and commercialization of the MIDS Cardiac™ hand-held technology for the early detection of heart a...
Healthcare technology company Zenosense (OTC: ZENO), a co-owner of the United Kingdom’s MIDS Medical Limited (“MML”) and its innovative handheld MIDS technology, is engaged in the ongoing development of its innovative MIDS Cardiac device. A recent article about the company...
Company’s MIDS Cardiac device aims to help ER personnel perform quick, high-sensitivity analysis of heart events MIDS device’s handheld portability is being developed to allow quick-response resource to minimally trained ambulance personnel Final device could ultimately he...
Zenosense (OTC: ZENO), a healthcare technology company, this morning announced that its MIDS Medical Ltd. (“MML") joint venture (“JV”) has entered a staged funding for the next phase of development of the MIDS Cardiac™ hand-held technology. MML entered into an agree...
Palm Beach, FL – (September 5, 2018) – Heart disease is one of the leading causes of death in the western world. In Europe and the U.S. alone, it is estimated 15 to 20 million patients a year visit the emergency departments of hospitals reporting chest pain that could be a sign of ...
VALENCIA, SPAIN, Sept. 05, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Zenosense, Inc. (OTCQB: ZENO, "Zenosense", the "Company"), a healthcare technology company focused on the development and commercialization of the MIDS Cardiac™ hand-held technology for the early detection of hea...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK , June 5, 2019 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the lists of downgrades from its respective OTCQX® and OTCQB® markets and Caveat Emptor Desig...
VALENCIA, SPAIN, March 20, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Zenosense, Inc. (OTCQB: ZENO, "Zenosense", the "Company"), a healthcare technology company focused on the development and commercialization of the MIDS Cardiac™ hand-held technology for the early detection o...
Agreement signed with third party investor to fund up to $1.2 million to support next crucial development phase of MIDS Cardiac POC diagnostic device Patented MIDS technology has successfully detected commercial assay beads at a level approximately four times better than the threshold adv...